Today we announced our First Quarter 2024 Financial Results and provided a company update. Review our progress to date and the milestones for 2024: https://lnkd.in/gv8rxfJM
Pliant Therapeutics’ Post
More Relevant Posts
-
#InvestorNews: #EYPT to report Q4 2023 financial results and recent corporate developments at our upcoming webcast. Learn more below:
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024 | EyePoint Pharmaceuticals
investors.eyepointpharma.com
To view or add a comment, sign in
-
I am privileged to lead a special team at Ovid Therapeutics . As we await the outcome of the Phase 3 results from soticlestat, targeted to those suffering from Dravet and Lennox-Gastaut syndrome, the team have built a unique clinical pipeline of other potential first or best in class medicines for epilepsies and rare disorders of the brain and exciting platforms to discover still others. The team will not only advance the clinical programs but also they are going to fully exploit the opportunities we are uncovering in the exciting and broad preclinical platforms we have targeting ROCK2 and KCC2. These targets offer opportunities that may open up multiple other compelling first in class and only in class CNS medicines. Neurosciences is breaking open. Just as Immuno-oncology did a decade ago. #epilepsy #neurosciences #depression #migraine #alzheimers #soticlestat #
Today, we reported our second quarter 2023 financial results and business updates. Read the full release by clicking the link below.
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
investors.ovidrx.com
To view or add a comment, sign in
-
Tomorrow, we will announce our financial results for the 2nd quarter of 2023. All details in a nutshell: ➡️ 7 a.m. (CEST): Publication of our Q2 results ➡️ 9:30 a.m. (CEST): Media conference call ➡️ 2 p.m. (CEST): Conference call for analysts You can find further information here: https://lnkd.in/ew59HKhi #EMDresults #Q2 #FinancialResults
Half-Yearly Financial Report Q2/2023 | Merck KGaA, Darmstadt, Germany
emdgroup.com
To view or add a comment, sign in
-
We have just released our Q1 financial results. Find all the key figures and our full statement here: https://lnkd.in/dsWrDgdF #StevanatoGroup #FinancialResults #ManagingComplexityDeliveringValue
Stevanato Group Reports Financial Results for the First Quarter of 2024
ir.stevanatogroup.com
To view or add a comment, sign in
-
Tomorrow, we will announce our financial results for the 3rd quarter of 2023. All details in a nutshell: ➡️ 7 a.m. (CET): Publication of our Q3 results ➡️ 9:30 a.m. (CET): Media conference call ➡️ 2 p.m. (CET): Conference call for analysts You can find further information here: https://lnkd.in/eRmPRD-g #EMDresults #Q3 #FinancialResults
Q3 2023 Results | Merck KGaA, Darmstadt, Germany
emdgroup.com
To view or add a comment, sign in
-
The field of financial navigation....such an important role.
Academy of Oncology Nurse & Patient Navigators (AONN ) - Role of the Financial Navigator
aonnonline.org
To view or add a comment, sign in
-
Antibody drug conjugates (ADCs) are an important new modality that is showing great results in treating certain types of cancer. Manufacture of this drug class is complex insofar as it requires several GMP intermediates as inputs to the conjugation reaction to produce the drug substance. My team of technical consultants at Alira Health has a focus on biologics, and we do a lot of work with ADCs. I'm excited to announce publication of an article from my team entitled “Manufacturing challenges of therapeutic antibody-drug conjugates” by Dr. Peter Alexander and colleagues. The article appears as a featured report in the September 2023 issue of BioProcess International. Read the full article here: https://lnkd.in/gs_TyPe4
September 2023 - Featured Report
secure.viewer.zmags.com
To view or add a comment, sign in
-
As Total Market Solutions' article demonstrates, in its focus on OCT, “the commercial reward may be very great for investors prepared to stay the course through the regulatory and financial challenges the company will have to negotiate”. Read more below ⬇️ https://lnkd.in/dnQzSnsU
Oxford Cannabinoid Technologies PLC - Total Market Solutions
https://total-market-solutions.com
To view or add a comment, sign in
-
Learn more about stakeholder impact facts and stats in the #MRxReport!
Magellan Rx Management’s Post
linkedin.com
To view or add a comment, sign in